



PHARMACY REVIEW SERVICES PHONE: (206) 901-4700

FAX: (800) 377-8853

PATIENT:			
DOB:		MEMBER #:	
PRESCRIBER:		ALT #:	
ADMIN LOCATION:		DX CODE (S):	
	Tecartus (brexucab	agene autoleud	-el)
Offic	ce Administered Prior Auth	_	<u> </u>
	se provide any or all clinical of		•
		·	
	hia Chromosome Negative eck all criteria that apply below)	Acute Lympno	biastic Leukemia Pn(-):
•		nd has less than CR	after extended remission induction
	tient is 40 years and older who is n		
☐ YES ☐ NO (If YES, che ☐ YES ☐ NO Pa	hia Chromosome Positive Act all criteria that apply below) tient has received intensive chemo AND YES NO Patient is not MRD	therapy with TKI the	тару
☐ YES ☐ NO (If YES, che ☐ YES ☐ NO Pa additional novel ch ☐ YES ☐ NO Pa	or Refractory Mantle Cell Leck all criteria that apply below) tient has Stage I, II disease post promemotherapy resulting in partial respitient has relapse after Stem cell tractient has stage II (bulky), III, IV for partial respitient has stage II (bulky), III, IV for partial respirations.	-ymphoma ior chemotherapy +loonse or refractory onsplant	RT followed by BTK inhibitor or disease
☐ YES ☐ NO Burkitt's lyn ☐ YES ☐ NO Active hepa ☐ YES ☐ NO Active Grace	ititis B, C, or any uncontrolled infect le 2 to 4 Graft versus Host Disease	ion? (GVHD)?	: 5/mL with blasts on cytocentrifuge

Authorization duration: limited to a one-time (single infusion) treatment

and/or signs of CNS leukemia (e.g., cranial nerve palsy)?